A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer - a study of the OVCAD consortium

BackgroundThe immune system is a key player in fighting cancer. Thus, we sought to identify a molecular ‘immune response signature’ indicating the presence of epithelial ovarian cancer (EOC) and to combine this with a serum protein biomarker panel to increase the specificity and sensitivity for earlier detection of EOC.MethodsComparing the expression of 32,000 genes in a leukocytes fraction from 44 EOC patients and 19 controls, three uncorrelated shrunken centroid models were selected, comprised of 7, 14, and 6 genes. A second selection step using RT-qPCR data and significance analysis of microarrays yielded 13 genes (AP2A1, B4GALT1, C1orf63, CCR2, CFP, DIS3, NEAT1, NOXA1, OSM, PAPOLG, PRIC285, ZNF419, and BC037918) which were finally used in 343 samples (90 healthy, six cystadenoma, eight low malignant potential tumor, 19 FIGO I/II, and 220 FIGO III/IV EOC patients). Using new 65 controls and 224 EOC patients (thereof 14 FIGO I/II) the abundances of six plasma proteins (MIF, prolactin, CA125, leptin, osteopondin, and IGF2) was determined and used in combination with the expression values from the 13 genes for diagnosis of EOC.ResultsCombined diagnostic models using either each five gene expression and plasma protein abundance values or 13 gene expression and six plasma protein abundance values can discriminate controls from patients with EOC with Receiver Operator Characteristics Area Under the Curve values of 0.998 and bootstrap .632+ validated classification errors of 3.1% and 2.8%, respectively. The sensitivities were 97.8% and 95.6%, respectively, at a set specificity of 99.6%.ConclusionsThe combination of gene expression and plasma protein based blood derived biomarkers in one diagnostic model increases the sensitivity and the specificity significantly. Such a diagnostic test may allow earlier diagnosis of epithelial ovarian cancer.

[1]  Hongyu Zhao,et al.  Serum protein markers for early detection of ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[4]  D. Ward,et al.  Diagnostic Markers for Early Detection of Ovarian Cancer , 2008, Clinical Cancer Research.

[5]  J. Marks,et al.  Development of a multimarker assay for early detection of ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  W. Liang,et al.  TM4 microarray software suite. , 2006, Methods in enzymology.

[7]  B. Brandt,et al.  Two-layer buoyant density centrifugation gradient for enrichment of prostate-derived cells and cell clusters from peripheral blood. , 1996, Clinical chemistry.

[8]  R. Bast,et al.  Reactivity of a monoclonal antibody with human ovarian carcinoma. , 1981, The Journal of clinical investigation.

[9]  R. Bast,et al.  Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer , 2004, Cancer Research.

[10]  Mee Young Park,et al.  L 1-regularization path algorithm for generalized linear models , 2006 .

[11]  W. Liang,et al.  9) TM4 Microarray Software Suite , 2006 .

[12]  Zhen Zhang,et al.  Effectiveness of a Multivariate Index Assay in the Preoperative Assessment of Ovarian Tumors , 2011, Obstetrics and gynecology.

[13]  P Maisonneuve,et al.  Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[14]  Usha Menon,et al.  Progress and Challenges in Screening for Early Detection of Ovarian Cancer* , 2004, Molecular & Cellular Proteomics.

[15]  K. Shuai,et al.  Regulation of JAK–STAT signalling in the immune system , 2003, Nature Reviews Immunology.

[16]  S. Mabuchi,et al.  Treatment of ovarian cancer by monoclonal antibodies. , 2010, Discovery medicine.

[17]  G. Sawaya,et al.  Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay. , 2011, Obstetrics and gynecology.

[18]  Roger E Bumgarner,et al.  Multiclass classification of microarray data with repeated measurements: application to cancer , 2003, Genome Biology.

[19]  Robert Tibshirani,et al.  Fataluku medicinal ethnobotany and the East Timorese military resistance , 2007, Journal of ethnobiology and ethnomedicine.

[20]  A. Børresen-Dale,et al.  Gene expression profiling of peripheral blood cells for early detection of breast cancer , 2010, Breast Cancer Research.

[21]  Mee Young Park,et al.  L1‐regularization path algorithm for generalized linear models , 2007 .

[22]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[23]  T. Bourne,et al.  Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay. , 2011, Obstetrics and gynecology.

[24]  Hys Ngan,et al.  Carcinoma of the Ovary , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[25]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[26]  R. Tibshirani,et al.  Improvements on Cross-Validation: The 632+ Bootstrap Method , 1997 .

[27]  Richard G. Moore,et al.  Current clinical use of biomarkers for epithelial ovarian cancer , 2010, Current opinion in oncology.